CAGRILINTIDE
Cagrilintide is a long‑acting acylated analogue of the pancreatic hormone amylin, designed for once‑weekly subcutaneous administration. It activates central amylin receptors to promote satiety, slow gastric emptying, and reduce food intake. In phase 2 and phase 3 trials, cagrilintide produced dose‑dependent weight loss with a predominantly gastrointestinal side‑effect profile
Reconstitution Steps
Draw 3.0 mL bacteriostatic water with a sterile syringe.
Inject slowly down the vial wall; avoid foaming or vigorous agitation.
Gently swirl or roll until fully dissolved (do not shake).
Label with date and concentration; refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Use within 30 days of reconstitution; discard if cloudy or particulate matter appears.
Protocol Overview
Concise summary of the once‑weekly regimen.
Goal: Support satiety, reduce food intake, and promote weight management over time
Schedule: Weekly subcutaneous injections for 12–16 weeks (or longer as appropriate).
Dose Range: 0.6–4.5 mg weekly with gradual titration every 2 weeks.
Reconstitution: 3.0 mL per 10 mg vial (~3.33 mg/mL) for practical volume measurements.
Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw cycles.
Dosing Protocol
Suggested daily titration approach reflecting clinical study parameters.
Start: 0.6 mg weekly for the first 2 weeks to assess tolerability.
Escalate: Double the dose every 2 weeks (0.6 → 1.2 → 2.4 → 4.5 mg) as tolerated.
Target: 4.5 mg weekly by Weeks 7–8; maintain at this dose.
Frequency: Once per week (subcutaneous) on the same day each week.
Timing: Any consistent time; rotate injection sites.
Storage Instructions
Proper storage preserves peptide quality.
Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; minimize moisture exposure.
Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within 30 days and avoid freeze–thaw cycles.
Allow vials to reach room temperature before opening to reduce condensation uptake.
Important Notes
Practical considerations for consistency and safety.
Use new sterile syringes for each injection; dispose in a sharps container.
Rotate injection sites (abdomen, thighs, upper arms) weekly to reduce local irritation.
Gradual dose escalation minimizes gastrointestinal side effects such as nausea
Document weekly dose, injection site, and any adverse effects to maintain consistency.
For maintenance doses requiring >1.0 mL, ensure you have appropriately sized syringes (3 mL).
How This Works
Cagrilintide is an acylated, long‑acting analogue of amylin—a hormone co‑secreted with insulin from pancreatic beta cells. Native amylin promotes satiation, slows gastric emptying, and inhibits postprandial glucagon secretion/ By acting on central amylin receptors (particularly in the area postrema and hindbrain), cagrilintide reduces appetite and energy intake. Lipid modifications extend its half‑life to approximately 160–195 hours, enabling once‑weekly dosing.
Potential Benefits
Weight reduction: In the phase 2 trial, cagrilintide 4.5 mg weekly produced approximately 10.8% body weight loss over 26 weeks versus 3.0% with placebo.
Combination therapy: When combined with semaglutide 2.4 mg (CagriSema), phase 3 REDEFINE trials showed approximately 20% weight loss at 68 weeks, exceeding results with either agent alone.
Dose‑dependent efficacy: Higher doses (2.4–4.5 mg) demonstrate greater weight loss than lower doses (0.3–1.2 mg)
Side effects: Primarily gastrointestinal—nausea, vomiting, diarrhea, and constipation—which are generally mild‑to‑moderate and transient. Gradual titration helps minimize these effects.
Injection‑site reactions: Occasional mild redness or irritation at subcutaneous injection sites.
Lifestyle Factors
Complementary strategies that may support therapeutic goals.
Pair with a balanced, protein‑forward diet tailored to individual energy needs.
Combine resistance training and aerobic activity to support metabolic health and preserve lean mass.
Prioritize adequate sleep (7–9 hours) and stress management for adherence and recovery.
Monitor hydration and electrolytes, especially if experiencing gastrointestinal side effects.
